Welcome to our dedicated page for Dyadic International news (Ticker: DYAI), a resource for investors and traders seeking the latest updates and insights on Dyadic International stock.
Dyadic International, Inc. (OTCQX: DYAI) is a global biotechnology company renowned for its pioneering work in gene expression systems. The company has developed the C1 Expression System, a patented and proprietary technology utilizing the Thermothelomyces heterothallica fungus, which has set new standards in the production of commercial quantities of industrial enzymes and other proteins. This innovative platform is licensed to industry giants like Abengoa Bioenergy, BASF, and Codexis for various non-pharmaceutical applications.
Core Business
Dyadic's core business revolves around the advancement and application of the C1 Expression System. This platform is instrumental in producing biologic vaccines and drugs at a faster rate, in larger volumes, and at a lower cost, thereby making healthcare more accessible and affordable. By enhancing protein production capabilities, Dyadic aims to meet the growing demands of drug developers and manufacturers, ultimately improving patient care and saving lives.
Recent Achievements and Current Projects
Dyadic has made significant strides in the biotechnology sector. The company has successfully showcased the efficiency of the C1 Expression System in various industrial applications. Currently, Dyadic is focusing on expanding its influence in the pharmaceutical sector, aiming to leverage C1's potential for large-scale production of human and animal vaccines and therapeutics.
Financial Condition
With a solid financial foundation, Dyadic continues to invest in research and development, ensuring the continuous improvement of its gene expression technology. The company's partnerships and licensing agreements with major industry players underscore its financial stability and growth potential.
Partnerships and Collaborations
Dyadic's collaborative efforts with companies like Abengoa Bioenergy, BASF, and Codexis highlight its pivotal role in the biotechnology landscape. These partnerships enable Dyadic to expand the application of the C1 Expression System beyond pharmaceuticals, touching sectors such as food, nutrition, and wellness.
Products and Services
Dyadic's primary product, the C1 Expression System, is a game-changer in gene expression and protein production. The company is dedicated to advancing this technology to meet the evolving needs of the biopharmaceutical industry, ensuring more efficient and cost-effective production processes.
Contact Information
For further information, inquiries can be directed to Ping W. Rawson, Chief Financial Officer, at (561) 743-8333 or via email at ir@dyadic.com.
Dyadic International announced the publication of a study demonstrating its vaccine candidate DYAI-100, a recombinant protein RBD booster for COVID-19, has shown promise in animal models. The study, published in VACCINES, supports the upcoming First-In-Human clinical trial aimed at evaluating safety and immune response. The vaccine demonstrated strong immunogenicity and antiviral efficacy without adverse effects. Importantly, the C1-cell production platform offers a cost-effective and scalable manufacturing process, reinforcing Dyadic's commitment to producing affordable biopharmaceuticals.
Dyadic International received regulatory approval from SAHPRA to initiate a Phase 1 clinical trial for its COVID-19 vaccine candidate, DYAI-100. The company presented significant data at the World Vaccine Congress Europe and announced new collaborations in animal health. As of September 30, 2022, cash and investments totaled $14.2 million. Research and development revenues increased to approximately $880,000 for Q3 2022. Net loss for the quarter was about $1.8 million, consistent with the prior year, but the loss per share improved over nine months.
Dyadic International (NASDAQ: DYAI), a biotechnology firm, has announced participation in key industry events in November 2022, aimed at enhancing its microbial platforms for protein production and biopharmaceutical needs. Key conferences include the RAFT® 14 Conference (Nov 6-9) in Orlando, where CEO Mark Emalfarb will present on Nov 8. Additionally, Dyadic will join the BARDA Industry Day (Nov 15-16) virtually and the Jefferies London Healthcare Conference (Nov 16-19). These events focus on connecting with investors and showcasing advancements in biopharmaceutical products.
Dyadic International, Inc. (NASDAQ: DYAI) will report its third quarter 2022 financial results and conduct a corporate update call on November 10, 2022, at 5:00 PM ET. The company focuses on innovative microbial platforms to enhance global protein production and develop affordable biopharmaceuticals for human and animal health. Its proprietary technologies include the C1-cell protein production platform and Dapibus™ for large-scale manufacturing of proteins. Dyadic aims to expedite the development of biologic products, including its DYAI-100 COVID-19 vaccine candidate.
Dyadic International (NASDAQ: DYAI) has received regulatory approval from the South African Health Products Regulatory Authority for a Phase 1 clinical trial of its DYAI-100 COVID-19 booster vaccine. This randomized, double-blind, placebo-controlled trial will assess the vaccine's safety and preliminary efficacy, with patient enrollment set to begin in South Africa later this year. Dyadic's CEO, Mark Emalfarb, expressed optimism about this milestone, while the partner Rubic Consortium emphasized its significance for improving vaccine access in underserved regions.
Dyadic International (NASDAQ: DYAI) announced that its CEO, Mark Emalfarb, will present at the World Vaccine Congress from October 11-14, 2022 in Barcelona, Spain. The presentation will showcase advancements in expressing Omicron BA.5 and other antigens, aiming to enhance vaccine efficacy against viruses, including COVID-19 variants. Notably, the C1-cell platform allows for efficient antigen production at 10 grams per liter. Collaboration with Dr. Albert Osterhaus will also be highlighted. Interested parties can register for the event or request meetings.
Dyadic International, Inc. (NASDAQ: DYAI) provided updates on its C1 protein production platform, showcasing advancements in protein yield and overall productivity. Key achievements include a nine-fold increase in the expression yield for Nivolumab, and successful expression of several COVID-19 variants, including Omicron. The C1 platform demonstrated significant potential for accelerating vaccine development and lowering production costs. The company anticipates data presentations at upcoming industry conferences and details a planned Phase 1 clinical trial for its COVID-19 recombinant protein booster vaccine.
Dyadic International (NASDAQ: DYAI), a biotechnology firm, has announced its participation in several key industry events in September 2022. The company will present at the H.C. Wainwright 24th Annual Global Investment Conference from September 12-14, followed by a panel at the World Health Organization consultation on September 13-14. Additionally, Dyadic will participate in the Vaccine Technology Summit and BioProcess International. The management will be available for one-on-one meetings during these events to discuss their innovative microbial platforms aimed at enhancing global protein production and biopharmaceutical products.
Dyadic International announced the submission of a Clinical Trial Application (CTA) for its DYAI-100 COVID-19 vaccine to South Africa's SAHPRA, marking a significant milestone for its C1-cell protein production platform. The CTA supports a Phase 1 study focusing on safety and efficacy. The company reported cash and investments of $15.7 million as of June 30, 2022, and noted a decrease in revenue and expenses in the second quarter compared to the previous year. A conference call to discuss financial results is scheduled for August 10, 2022, at 5:00 PM EST.
Dyadic International, Inc. (NASDAQ: DYAI) announced it will report its second-quarter 2022 financial results and host a corporate update call on August 10, 2022, at 5:00 p.m. ET. The company focuses on enhancing its proprietary C1-cell protein production platform for biologic vaccines and drugs, aiming to lower costs and improve performance. Investors can access the live conference via provided dial-in numbers and a webcast link. An archive will be available post-event on Dyadic's website.
FAQ
What is the current stock price of Dyadic International (DYAI)?
What is the market cap of Dyadic International (DYAI)?
What does Dyadic International, Inc. do?
What is the C1 Expression System?
Who are Dyadic's partners?
What sectors does Dyadic serve?
How does Dyadic's C1 Expression System benefit the healthcare sector?
Where is Dyadic International, Inc. headquartered?
What recent projects is Dyadic working on?
How can I contact Dyadic for more information?
What is Dyadic's stock symbol?
What is the main goal of Dyadic International, Inc.?
